News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
845,018 Results
Type
Article (86362)
Company Profile (651)
Press Release (758005)
Multimedia
Podcasts (129)
Webinars (14)
Section
Business (232615)
Career Advice (4126)
Deals (39718)
Drug Delivery (129)
Drug Development (90932)
Employer Resources (198)
FDA (18077)
Job Trends (17330)
News (396293)
Policy (39729)
Tag
Academia (2998)
Academic (1)
Accelerated approval (6)
Adcomms (26)
Allergies (92)
Alliances (56816)
ALS (98)
Alzheimer's disease (1493)
Antibody-drug conjugate (ADC) (150)
Approvals (18055)
Artificial intelligence (293)
Autoimmune disease (27)
Automation (16)
Bankruptcy (403)
Best Places to Work (12616)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (448)
Bladder cancer (81)
Brain cancer (30)
Breast cancer (292)
Cancer (2380)
Cardiovascular disease (199)
Career advice (3533)
Career pathing (34)
CAR-T (169)
Cell therapy (474)
Cervical cancer (20)
Clinical research (73318)
Collaboration (898)
Compensation (535)
Complete response letters (28)
COVID-19 (2861)
CRISPR (48)
C-suite (259)
Cystic fibrosis (106)
Data (2249)
Decentralized trials (2)
Denatured (45)
Depression (50)
Diabetes (279)
Diagnostics (6901)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (131)
Drug pricing (119)
Drug shortages (29)
Duchenne muscular dystrophy (100)
Earnings (96529)
Editorial (42)
Employer branding (25)
Employer resources (167)
Events (129820)
Executive appointments (753)
FDA (19363)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (791)
Gene editing (119)
Generative AI (26)
Gene therapy (352)
GLP-1 (829)
Government (5149)
Grass and pollen (5)
Guidances (59)
Healthcare (20862)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (139)
Indications (30)
Infectious disease (3010)
Inflammatory bowel disease (151)
Inflation Reduction Act (11)
Influenza (54)
Intellectual property (100)
Interviews (812)
IPO (17810)
IRA (48)
Job creations (5187)
Job search strategy (2861)
Kidney cancer (11)
Labor market (42)
Layoffs (551)
Leadership (23)
Legal (10101)
Liver cancer (81)
Lung cancer (338)
Lymphoma (157)
Machine learning (7)
Management (65)
Manufacturing (339)
MASH (73)
Medical device (14602)
Medtech (14607)
Mergers & acquisitions (22427)
Metabolic disorders (756)
Multiple sclerosis (85)
NASH (23)
Neurodegenerative disease (110)
Neuropsychiatric disorders (33)
Neuroscience (2079)
NextGen: Class of 2025 (7667)
Non-profit (5079)
Now hiring (40)
Obesity (405)
Opinion (273)
Ovarian cancer (78)
Pain (93)
Pancreatic cancer (86)
Parkinson's disease (156)
Partnered (23)
Patents (246)
Patient recruitment (114)
Peanut (51)
People (65233)
Pharmaceutical (133)
Pharmacy benefit managers (21)
Phase I (22633)
Phase II (31839)
Phase III (23985)
Pipeline (1224)
Policy (166)
Postmarket research (3551)
Preclinical (10213)
Press Release (72)
Prostate cancer (110)
Psychedelics (37)
Radiopharmaceuticals (267)
Rare diseases (419)
Real estate (7391)
Recruiting (75)
Regulatory (26733)
Reports (57)
Research institute (2653)
Resumes & cover letters (649)
Rett syndrome (5)
RNA editing (5)
RSV (44)
Schizophrenia (78)
Series A (141)
Series B (90)
Service/supplier (27)
Sickle cell disease (58)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4291)
State (2)
Stomach cancer (14)
Supply chain (70)
Tariffs (45)
The Weekly (82)
Vaccines (799)
Venture capitalists (44)
Weight loss (286)
Women's health (40)
Worklife (20)
Date
Today (169)
Last 7 days (890)
Last 30 days (2747)
Last 365 days (34757)
2025 (11140)
2024 (37556)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1270)
Alabama (60)
Alaska (7)
Arizona (265)
Arkansas (14)
Asia (50096)
Australia (8826)
California (6341)
Canada (2040)
China (555)
Colorado (279)
Connecticut (284)
Delaware (154)
Europe (114809)
Florida (928)
Georgia (214)
Hawaii (1)
Idaho (64)
Illinois (604)
India (29)
Indiana (321)
Iowa (12)
Japan (165)
Kansas (111)
Kentucky (25)
Louisiana (13)
Maine (67)
Maryland (952)
Massachusetts (4855)
Michigan (232)
Minnesota (414)
Mississippi (2)
Missouri (84)
Montana (30)
Nebraska (26)
Nevada (65)
New Hampshire (67)
New Jersey (1793)
New Mexico (30)
New York (1793)
North Carolina (1113)
North Dakota (9)
Northern California (2719)
Ohio (211)
Oklahoma (15)
Oregon (46)
Pennsylvania (1408)
Puerto Rico (13)
Rhode Island (35)
South America (1652)
South Carolina (22)
South Dakota (1)
Southern California (2340)
Tennessee (102)
Texas (942)
United States (24270)
Utah (186)
Virginia (158)
Washington D.C. (66)
Washington State (592)
West Virginia (3)
Wisconsin (57)
845,018 Results for "treos bio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting.
May 8, 2024
·
2 min read
Genetown
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
Treos Bio Limited announced the presentation of results from its phase 2 OBERTO-301 study of the company’s lead product candidate, PolyPEPI1018, in combination with atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 American Society of Clinical Oncology Annual Meeting.
June 3, 2024
·
7 min read
Press Releases
New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
September 10, 2024
·
3 min read
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Hillstar Bio Nets $67M Series A to Advance Autoimmune and Arthritis Pipeline
Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.
March 25, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
March 28, 2025
·
19 min read
Press Releases
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
April 2, 2025
·
5 min read
Press Releases
FDA Grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-Cell Therapy for Incurable Pediatric Brain Tumors
April 22, 2025
·
5 min read
Press Releases
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
March 24, 2025
·
3 min read
Press Releases
Adaptin Bio, Inc., a Lucius Partners Portfolio Company, Completes Alternative Public Offering (APO) and Closes $7.7 Million Private Placement
April 7, 2025
·
6 min read
1 of 84,502
Next
